Legal News

The California board of pharmacy has decided to postpone its electronic pedigree rule that was expected to go into effectin January 2009

States vary in their laws regarding whether pharmacists can dispense when they receive a prescription ordered by the physician for himself or his family members

Ilisa Bernsteain, FDA's director of pharmacy affairs talks to Drug Topics about a variety of pharmacy issues, including e-pedigree, REMS plans, risk management plans and other issus.

Employers look to pharmacists to improve employees' chronic care to reduce healthcare costs and improve health.

The largest California independent living center, two pharmacies, and two Medi-Cal recipients sued Medi-Cal to set aside plans to cut reimbursement

The Centers for Medicare & Medicaid Services issues a final rule clarifying its position on the inclusion of insulin and exclusion of erectile dysfunction medications in the Medicare Part D program.

NCPA and the NACDS have amended their average manufacturer price lawsuit to include CMS' interim final rule on multiple-source drugs

Medical devices featuring the Carmeda BioActive surface from Medtronic are being recalled because they are made with the contaminated heparin made in China.

A large group of physicians, pharmacists, and patients have pressed Congress to urge FDA to rescind its policy that bars the use of compounded estriol to treat menopause.

In testimony before a House subcommittee, a homecare organization labels the DMEPOS competitive bidding program as a train wreck.

McKesson is settling allegations that it violated federal reporting provisions relating to its handling of controlled substances at six of its distribution centers.

In a settlement with the Connecticut attorney general, the Infectious Diseases Society of America agreed to evaluate its Lyme disease guidelines and use of antibiotics.

There has been an "explosion in interest" in pharmacy fraud and abuse (F&A) over the past few months.

The Centers for Medicare & Medicaid Services has issued an FAQ that explains about the use of a non-NPI for prescribers who are not covered entities.

In testimony before Congress, an NACDS executive argues that track and trace should not be required.

Since three steroids have a high potential for drug abuse and trafficking, the Drug Enforcement Administration wants to classify them as Schedule III controlled substances.

Industry discussed their views on comparative effectiveness of healthcare treatments.

A Wisconsin pharmacist is appealing to the state supreme court over sanctions imposed by the pharmacy board for failure to dispense birth control pills.

In testimony before a House subcommittee, the Government Accountability Office identifies weaknesses in the Food & Drug Administration's foreign drug inspection program.

An appeals court in D.C. said a suit PCMA filed against a D.C. law can go ahead in a lower court.

The Maryland legislature has passed five bills that regulate pharmacy benefit managers.

The National Association of Chain Drug Stores opposes new legislation that would create a federal e-pedigree requirement for tracking and tracing pharmaceuticals.

The Office of Inspector General has issued a new guide listing standards nursing facilities must comply with.

The Government Accountability Office urged Health & Human Services to prioritize practice recommendations from the Centers for Disease Control & Prevention in order to prevent hospital infections.

The National Association of Chain Drug Stores and the National Community Pharmacists Association criticize the Centers for Medicare & Medicaid Services' interim final rule on multiple-source drugs.

The Coalition Against Insurance Fraud has issued a report about the harmful effects of insurance fraud and what actions can be taken to prevent it from occurring.

Insmed has received a questionnaire from House of Representatives' Subcommittee on Health on develdoping legislation to establish a follow-on biologics regulatory pathway.

CMS will require Medicare Advantage annd prescription drug plan sponsors in the Medicare Part D program, cover more HIV retrovirals, include more MTM data, and specify prior authorization requirements.